Correlation Between Armata Pharmaceuticals and Salarius Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Armata Pharmaceuticals and Salarius Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Armata Pharmaceuticals and Salarius Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Armata Pharmaceuticals and Salarius Pharmaceuticals, you can compare the effects of market volatilities on Armata Pharmaceuticals and Salarius Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Armata Pharmaceuticals with a short position of Salarius Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Armata Pharmaceuticals and Salarius Pharmaceuticals.

Diversification Opportunities for Armata Pharmaceuticals and Salarius Pharmaceuticals

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Armata and Salarius is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Armata Pharmaceuticals and Salarius Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Salarius Pharmaceuticals and Armata Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Armata Pharmaceuticals are associated (or correlated) with Salarius Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Salarius Pharmaceuticals has no effect on the direction of Armata Pharmaceuticals i.e., Armata Pharmaceuticals and Salarius Pharmaceuticals go up and down completely randomly.

Pair Corralation between Armata Pharmaceuticals and Salarius Pharmaceuticals

Given the investment horizon of 90 days Armata Pharmaceuticals is expected to generate 2.85 times less return on investment than Salarius Pharmaceuticals. But when comparing it to its historical volatility, Armata Pharmaceuticals is 1.15 times less risky than Salarius Pharmaceuticals. It trades about 0.01 of its potential returns per unit of risk. Salarius Pharmaceuticals is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  150.00  in Salarius Pharmaceuticals on August 31, 2024 and sell it today you would lose (3.00) from holding Salarius Pharmaceuticals or give up 2.0% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Armata Pharmaceuticals  vs.  Salarius Pharmaceuticals

 Performance 
       Timeline  
Armata Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Armata Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable primary indicators, Armata Pharmaceuticals is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.
Salarius Pharmaceuticals 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Salarius Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Salarius Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Armata Pharmaceuticals and Salarius Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Armata Pharmaceuticals and Salarius Pharmaceuticals

The main advantage of trading using opposite Armata Pharmaceuticals and Salarius Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Armata Pharmaceuticals position performs unexpectedly, Salarius Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Salarius Pharmaceuticals will offset losses from the drop in Salarius Pharmaceuticals' long position.
The idea behind Armata Pharmaceuticals and Salarius Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments